• Christina Mitropoulou, PhD, MBA

CV

Christina Mitropoulou, PhD, MBA obtained her economics degree from the University of Athens (Greece), her MBA from NIMBAS in Utrecht (the Netherlands) and her PhD on economic evaluation in Pharmacogenomics and Precision Medicine from the Erasmus University in Rotterdam (the Netherlands). Christina is Managing Director and senior health economist at the Golden Helix Foundation (London, UK) and Adjunct Assistant Professor in the United Arab Emirates University, College of Medicine and Health Sciences, Department of Genetics and Genomics. Christina is leading the effort, as work package and Component Leader, to perform cost-effectiveness analysis and health technology assessment in two prospective pharmacogenomics clinical studies, the PREPARE study in Europe and the Em-HEART, a prospective pharmacogenomics clinical trial for cardiovascular disease patients in the United Arab Emirates. With a strong background in economics, she has been responsible for several projects with academic and governmental organizations pertaining to economic evaluation and health technology assessment in genomic medicine and pharmacogenomics, particularly in developing countries. She has also co-authored two textbooks on Economic Evaluation in Genomic Medicine, published by Elsevier/Academic Press in 2015 and 2023.

ABSTRACT

Cost effectiveness analysis: Results of the PREPARE study in Europe

1 The Golden Helix Foundation, London, UK.

2 Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, Abu Dhabi, United Arab Emirates.

Email: [email protected]

 

 

Pharmacogenetics (PGx) aims to revolutionize healthcare by individualizing drug doses and medication choices. However, clinical uptake will require positive evaluation evidence of both clinical utility and cost-effectiveness. We have recently demonstrated the clinical utility of this approach, using a panel-based PGx-guided treatment of patients from various indications recruited in seven countries (PREPARE study). Here, we provide economic evidence from a cost-utility analysis of PGx-guided treatment in patients participating in the PREPARE study. We used the national healthcare system’s perspective in each participating country, including only direct medical costs that budget holders cover. A Visual Analog Scale was used to measure utility and the quality of life was estimated by averaging the Visual Analog Scale scores of participants over four specific time points in the study. Our data suggest that panel-based PGx testing is cost-effective, and in some cases even a dominant, choice, which, together with the clinically beneficial outcomes already demonstrated in the PREPARE study, provides additional evidence of the need to implement PGx into clinical practice.